<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30389659</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>03</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1078-0432</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>02</Day>                    </PubDate>                </JournalIssue>                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">clincanres.1889.2018</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-18-1889</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">A major issue for the effective treatment of brain metastasis is the late stage of diagnosis with existing clinical tools. The aim of this study was to evaluate the potential of vascular cell adhesion molecule-1 (VCAM-1) targeted magnetic resonance imaging (MRI) for early detection of brain micrometastases in mouse models across multiple primary tumour types.</AbstractText>                <AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Xenograft models of brain micrometastasis for human breast carcinoma (MDA231Br-GFP), lung adenocarcinoma (SEBTA-001) and melanoma (H1_DL2) were established via intracardiac injection in mice. Animals (n=5-6/group) were injected intravenously with VCAM-1 targeted microparticles of iron oxide (VCAM-MPIO) and, subsequently, underwent <i>T</i><sub>2</sub>*-weighted MRI. Control groups of naïve mice injected with VCAM-MPIO and tumour-bearing mice injected with non-targeting IgG-MPIO were included.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All models showed disseminated micrometastases in the brain, together with endothelial VCAM-1 upregulation across the time-course. <i>T</i><sub>2</sub>*-weighted MRI of all tumour-bearing mice injected with VCAM-MPIO showed significantly more signal hypointensities (p&lt;0.001; two-sided) than control cohorts, despite a lack of blood-brain barrier impairment. Specific MPIO binding to VCAM-1 positive tumour-associated vessels was confirmed histologically. VCAM-1 expression was demonstrated in human brain metastasis samples, across all three primary tumour types.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">VCAM-1-targeted MRI enables detection of brain micrometastases from the three primary tumour types known to cause the majority of clinical cases. These findings represent an important step forward in the development of a broadly applicable and clinically relevant imaging technique for early diagnosis of brain metastasis, with significant implications for improved patient survival.</AbstractText>                <CopyrightInformation>Copyright ©2018, American Association for Cancer Research.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cheng</LastName>                    <ForeName>Vinton W T</ForeName>                    <Initials>VWT</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology, CRUK/MRC Oxford Institute for Radiation Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarmiento Soto</LastName>                    <ForeName>Manuel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology, University of Oxford.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Khrapitchev</LastName>                    <ForeName>Alexandre A</ForeName>                    <Initials>AA</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7616-6635</Identifier>                    <AffiliationInfo>                        <Affiliation>Oncology, CRUK/MRC Oxford Institute for Radiation Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Perez-Balderas</LastName>                    <ForeName>Francisco</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Oncology, CRUK/MRC Oxford Institute for Radiation Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zakaria</LastName>                    <ForeName>Rasheed</ForeName>                    <Initials>R</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0001-6826-2662</Identifier>                    <AffiliationInfo>                        <Affiliation>Institute of Integrative Biology, University of Liverpool.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jenkinson</LastName>                    <ForeName>Michael D</ForeName>                    <Initials>MD</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4587-2139</Identifier>                    <AffiliationInfo>                        <Affiliation>Institute of Translational Medicine, University of Liverpool.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Middleton</LastName>                    <ForeName>Mark R</ForeName>                    <Initials>MR</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0003-0167-1685</Identifier>                    <AffiliationInfo>                        <Affiliation>Oncology, University of Oxford.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sibson</LastName>                    <ForeName>Nicola</ForeName>                    <Initials>N</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0003-1211-2766</Identifier>                    <AffiliationInfo>                        <Affiliation>ONCOLOGY, University of Oxford nicola.sibson@oncology.ox.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Cancer Res</MedlineTA>            <NlmUniqueID>9502500</NlmUniqueID>            <ISSNLinking>1078-0432</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30389659</ArticleId>            <ArticleId IdType="pii">1078-0432.CCR-18-1889</ArticleId>            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1889</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>